Drug intelligence / Profile preview

ELI-011

Development stage: Unknown
Lead developer: Elicio Therapeutics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies

Overview

ELI-011 is a preclinical **CD19-directed cell and gene therapy program** from **Elicio Therapeutics**. Based on the provided context, it is intended to target **B-lymphocyte antigen CD19** and involves **gene transference** and **T lymphocyte replacement**, consistent with an engineered T-cell approach aimed at CD19-expressing B cells. The asset appears to be an early-stage investigational immunotherapy program, with no marketed name, formulation, or clinical-stage indication established in the supplied materials.

Targets

CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on ELI-011.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ELI-011.

Explore the full profile